Published in Mol Cell Biol on March 01, 2006
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
ATM activation and signaling under hypoxic conditions. Mol Cell Biol (2008) 1.84
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res (2010) 1.35
Global dissociation of HuR-mRNA complexes promotes cell survival after ionizing radiation. EMBO J (2011) 1.21
Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. J Biol Chem (2009) 1.14
Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor 1α (HIF-1α). PLoS One (2011) 1.09
Targeting hypoxic cells through the DNA damage response. Clin Cancer Res (2010) 1.04
Tumor hypoxia and genetic alterations in sporadic cancers. J Obstet Gynaecol Res (2011) 0.93
Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair (Amst) (2015) 0.93
Tumor hypoxia as a driving force in genetic instability. Genome Integr (2013) 0.92
Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci (2009) 0.91
ATM activation in hypoxia - causes and consequences. Mol Cell Oncol (2014) 0.86
Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy. J Struct Biol (2011) 0.84
Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1. Cell Cycle (2010) 0.80
Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding. J Biol Chem (1975) 0.78
Hypoxia-induced alterations of G2 checkpoint regulators. Mol Oncol (2016) 0.77
X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket. FEBS Lett (2011) 0.77
Inhibition of NEDD8 and FAT10 ligase activities through the degrading enzyme NEDD8 ultimate buster 1: A potential anticancer approach. Oncol Lett (2016) 0.75
The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem (2016) 0.75
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (2003) 20.13
Universal control mechanism regulating onset of M-phase. Nature (1990) 19.11
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev (2001) 12.46
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev (2000) 11.49
The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer (1955) 10.49
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science (1998) 8.74
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science (1997) 8.43
DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 7.85
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A (2000) 5.64
Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J (1998) 5.25
Rapid destruction of human Cdc25A in response to DNA damage. Science (2000) 4.74
Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res (1990) 4.60
Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J (1993) 4.33
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature (2000) 3.65
Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol (1993) 3.63
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol (1994) 3.30
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res (2000) 3.06
Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J (1994) 2.95
Recombinant ATM protein complements the cellular A-T phenotype. Oncogene (1997) 2.95
CHK2 kinase--a busy messenger. Nat Rev Mol Cell Biol (2001) 2.68
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol (2004) 2.67
Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol (2000) 2.66
Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell (1993) 2.48
Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J (2002) 2.39
Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res (1995) 2.35
Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J (2004) 2.19
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem (2003) 2.18
DNA damage responses to oxidative stress. DNA Repair (Amst) (2004) 2.17
ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem (2003) 2.09
Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol (2002) 2.03
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem (1996) 2.01
The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem (2003) 1.84
Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem (2004) 1.63
p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol (2001) 1.53
Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res (1999) 1.50
Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther (2002) 1.49
Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx (2004) 1.44
Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res (2001) 1.43
Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene (2004) 1.42
De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. J Am Soc Nephrol (2001) 1.39
Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res (2002) 1.36
Oxidative stress and neuronal death/survival signaling in cerebral ischemia. Mol Neurobiol (2005) 1.36
A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene (2005) 1.32
Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene (2004) 1.31
A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene (1999) 1.29
The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst) (2004) 1.25
Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res (2005) 1.24
Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell (2005) 1.19
Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol (2000) 1.18
Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene (2001) 1.17
Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat Res (2003) 1.15
Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett (2001) 1.13
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer (1999) 1.13
Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des (1999) 1.06
Intracellular generation of reactive oxygen species in endothelial cells exposed to anoxia-reoxygenation. Am J Physiol (1997) 1.00
Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res (1996) 0.96
Reoxygenation after hypoxia and glucose depletion causes reactive oxygen species production by mitochondria in HUVEC. Am J Physiol Regul Integr Comp Physiol (2004) 0.95
Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett (2005) 0.87
Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp Lung Res (2002) 0.87
Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res (2001) 0.86
The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int J Radiat Oncol Biol Phys (1993) 0.86
Effect of hypoxia and reoxygenation on the formation and release of reactive oxygen species by porcine pulmonary artery endothelial cells. J Cell Physiol (1995) 0.85
Characterization of solid tumor microvasculature: a three-dimensional analysis using the polymer casting technique. Lab Invest (1988) 0.79
Hypoxia-induced irreversible S-phase arrest involves down-regulation of cyclin A. Cell Prolif (2003) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol (2002) 5.39
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell (2002) 3.86
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 3.68
JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell (2004) 3.30
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res (2004) 3.24
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med (2011) 2.97
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet (2005) 2.66
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
HIF1alpha delays premature senescence through the activation of MIF. Genes Dev (2006) 2.37
The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell (2005) 2.34
Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol (2006) 2.27
The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell (2012) 2.25
Investigating hypoxic tumor physiology through gene expression patterns. Oncogene (2003) 2.24
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A (2010) 2.19
Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol (2010) 2.17
ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem (2003) 2.09
Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev (2007) 2.07
Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol (2002) 2.03
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Hypoxic gene expression and metastasis. Cancer Metastasis Rev (2004) 2.01
Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol (2003) 1.99
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res (2003) 1.96
Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol (2005) 1.95
Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol (2007) 1.95
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev (2010) 1.92
OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell (2005) 1.91
MiR-210--micromanager of the hypoxia pathway. Trends Mol Med (2010) 1.90
Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest (2008) 1.89
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem (2002) 1.88
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell (2008) 1.88
ATM activation and signaling under hypoxic conditions. Mol Cell Biol (2008) 1.84
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell (2009) 1.82
Effect of reduced oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal cells. Am J Physiol Cell Physiol (2005) 1.76
Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation (2007) 1.71
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res (2006) 1.71
The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res (2009) 1.64
Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J Biol Chem (2004) 1.60
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development (2004) 1.58
Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res (2006) 1.53
Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res (2005) 1.52
AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50
The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun (2005) 1.48
Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol (2005) 1.45
Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell (2007) 1.41
Adaptive myogenesis under hypoxia. Mol Cell Biol (2005) 1.38
Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol (2006) 1.37
Angiogenesis is required for successful bone induction during distraction osteogenesis. J Bone Miner Res (2005) 1.36
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2007) 1.36
Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res (2010) 1.35
Short hairpin RNA interference therapy for ischemic heart disease. Circulation (2008) 1.34
Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol (2010) 1.34
The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget (2012) 1.33
The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol (2004) 1.33
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood (2009) 1.29
VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A (2011) 1.28
Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res (2004) 1.26
The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst) (2004) 1.25
Functional analysis of p53 binding under differential stresses. Mol Cell Biol (2006) 1.25
Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species. Mol Biol Cell (2010) 1.25
Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res (2010) 1.19
Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res (2006) 1.16
Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat Res (2003) 1.15
A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells. Autophagy (2012) 1.15
Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev (2004) 1.15
Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res (2011) 1.15
Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction. Circulation (2011) 1.14
In vitro expansion of adipose-derived adult stromal cells in hypoxia enhances early chondrogenesis. Tissue Eng (2007) 1.13
Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev (2013) 1.12
Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol (2006) 1.11
Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med (2013) 1.10
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene (2005) 1.10
PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol (2003) 1.10
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther (2006) 1.10
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem (2013) 1.09
Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor 1α (HIF-1α). PLoS One (2011) 1.09
Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell (2002) 1.06
Oxygen sensing and the DNA-damage response. Curr Opin Cell Biol (2007) 1.05
Targeting hypoxic cells through the DNA damage response. Clin Cancer Res (2010) 1.04
Hypoxia inducible factor-1alpha deficiency affects chondrogenesis of adipose-derived adult stromal cells. Tissue Eng (2007) 1.04
Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Clin Cancer Res (2009) 1.02
Inhibition of histone deacetylase activity in reduced oxygen environment enhances the osteogenesis of mouse adipose-derived stromal cells. Tissue Eng Part A (2009) 1.01
Neurotrophic factor GDNF promotes survival of salivary stem cells. J Clin Invest (2014) 1.01
Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res (2003) 1.01
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol (2009) 1.00